Clinical Trials

445 enrolled 18 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT00006721 2026-03-16

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

571 enrolled 12 charts

Lymphoma, Lymphoma, Follicular

NCT02213913 2026-03-11

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

55 enrolled 17 charts

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Intraocular Lymphoma

NCT06091254 2026-03-11

OLYMPIA-1

822 enrolled

Lymphoma, Follicular

NCT06149286 2026-03-06

OLYMPIA-5

470 enrolled

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT02339922 2026-03-05

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

33 enrolled 16 charts

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03789240 2026-03-03

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

33 enrolled 17 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT04542824 2026-03-03

EPCORE™ NHL-3

78 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-03-03

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT06191744 2026-03-03

EPCORE™FL-2

1,095 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT04224493 2026-03-02

SYMPHONY-1

612 enrolled

Lymphoma, Follicular

NCT05888493 2026-02-20

LEDA

109 enrolled

Lymphoma, Follicular, Recurrence

NCT06563596 2026-02-19

Epco, Zanu, Ritux for R/R FL or MZL

45 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT07418190 2026-02-18

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

33 enrolled

Lymphoma, Follicular

NCT05551936 2026-02-17

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

42 enrolled

Lymphoma, Follicular

NCT04998669 2026-02-10

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

100 enrolled

Lymphoma, Follicular

NCT06097364 2026-02-06

OLYMPIA-2

733 enrolled

Lymphoma, Follicular, Recurrence

NCT04712097 2026-02-04

Celestimo

478 enrolled

Lymphoma, Follicular, Recurrence

NCT04669171 2026-01-30

SIDNEY

Phase 1/2 Recruiting

80 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

LymphoidOther hematologic neoplasmSarcoma

803 enrolled 2 FDA

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT06425302 2026-01-08

GOLSEEK-2

90 enrolled

Lymphoma, Lymphoma, Follicular

NCT04680052 2025-12-22

InMIND

654 enrolled 40 charts 1 FDA

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT06911502 2025-12-05

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

400 enrolled

Lymphoma, Follicular

NCT02390869 2025-12-02

FIL_RENOIR12

128 enrolled

Phase 1 Not yet recruiting

Lymphoma, Follicular, Recurrence

NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

15 enrolled

Phase 1 Active not recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01479842 2025-10-15

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

48 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02180711 2025-10-15

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

113 enrolled 19 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT05371093 2025-10-15

ZUMA-22

231 enrolled

Lymphoma, Follicular

NCT01650701 2025-09-25

RELEVANCE

1,030 enrolled

Phase 3 Not yet recruiting

Lymphoma, Follicular

NCT07187960 2025-09-23

Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma

228 enrolled

Phase 1 Active not recruiting

Lymphoma, Follicular

NCT04447716 2025-09-15

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

4 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT00278408 2025-08-26

Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

700 enrolled 21 charts

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03424122 2025-08-21

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Phase 1 Completed

50 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05788081 2025-08-20

TOP-FLOR

40 enrolled

Lymphoma, Follicular

NCT06792825 2025-08-12

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

65 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT05409066 2025-07-28

EPCORE FL-1

549 enrolled 2 FDA

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT03401853 2025-07-22

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Phase 2 Terminated

18 enrolled 14 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT01996865 2025-07-10

MAGNIFY

503 enrolled 18 charts 1 FDA

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01974440 2025-05-25

SELENE

403 enrolled 23 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT01476787 2025-05-14

RELEVANCE

1,030 enrolled 12 charts

Lymphoma, Follicular

NCT01318317 2025-04-25

Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

8 enrolled 13 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT00848328 2025-04-24

Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma

Phase 2 Terminated

30 enrolled

Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01303887 2025-04-18

PACIFICO

680 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT03636503 2025-02-06

Rituximab + Immunotherapy in Follicular Lymphoma

Phase 1 Terminated

24 enrolled 25 charts

Lymphoma, Lymphoma, Follicular

NCT00670358 2025-01-10

Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

138 enrolled 16 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & NeckLymphoidPlasma cellSarcomaThoracic

169 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Lymphoma, Mantle-Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06704555 2024-11-26

Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma

20 enrolled

Lymphoma, Follicular

NCT04745832 2024-11-04

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Phase 3 Terminated

82 enrolled 11 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT03520920 2024-10-26

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

Phase 2 Completed

41 enrolled 25 charts